Temybric Ellipta Evrópusambandið - enska - EMA (European Medicines Agency)

temybric ellipta

glaxosmithkline trading services limited - fluticasone furoate, umeclidinium bromide, vilanterol trifenatate - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - temybric ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist or a combination of a long-acting β2-agonist and a long-acting muscarinic antagonist (for effects on symptom control and prevention of exacerbations see section 5.1).

TRELEGY ELLIPTA INHALATION POWDER 200 MCG62.5 MCG25 MCG Singapúr - enska - HSA (Health Sciences Authority)

trelegy ellipta inhalation powder 200 mcg62.5 mcg25 mcg

glaxosmithkline pte ltd - fluticasone furoate (micronised); umeclidinium bromide (micronised) eqv to umeclidinium; vilanterol trifenatate (micronised) eqv to vilanterol - powder, metered - fluticasone furoate (micronised) 200 mcg; umeclidinium bromide (micronised) eqv to umeclidinium 62.5 mcg; vilanterol trifenatate (micronised) eqv to vilanterol 25 mcg

TRELEGY ELLIPTA 100/62.5/25 fluticasone furoate 100 ug / umeclidinium (as bromide) 62.5 ug / vilanterol (as trifenatate) 25 ug powder for inhalation Ástralía - enska - Department of Health (Therapeutic Goods Administration)

trelegy ellipta 100/62.5/25 fluticasone furoate 100 ug / umeclidinium (as bromide) 62.5 ug / vilanterol (as trifenatate) 25 ug powder for inhalation

glaxosmithkline australia pty ltd - vilanterol trifenatate, quantity: 40 microgram (equivalent: vilanterol, qty 25 microgram); umeclidinium bromide, quantity: 74.2 microgram (equivalent: umeclidinium, qty 62.5 microgram); fluticasone furoate, quantity: 100 microgram - inhalation, powder for - excipient ingredients: lactose monohydrate; magnesium stearate - asthma,trelegy ellipta is indicated for the maintenance treatment of asthma in adult patients who are not adequately controlled with a combination of inhaled corticosteroid and a long-acting beta2-agonist.,copd,trelegy ellipta is indicated for the maintenance treatment of adults with moderate to severe copd who require treatment with lama+laba+ics.,trelegy ellipta is not indicated for the initiation of therapy in copd.

TRELEGY ELLIPTA 200/62.5/25 fluticasone furoate 200 ug / umeclidinium (as bromide) 62.5 ug / vilanterol (as trifenatate) 25 ug powder for inhalation Ástralía - enska - Department of Health (Therapeutic Goods Administration)

trelegy ellipta 200/62.5/25 fluticasone furoate 200 ug / umeclidinium (as bromide) 62.5 ug / vilanterol (as trifenatate) 25 ug powder for inhalation

glaxosmithkline australia pty ltd - vilanterol trifenatate, quantity: 40 microgram (equivalent: vilanterol, qty 25 microgram); umeclidinium bromide, quantity: 74.2 microgram (equivalent: umeclidinium, qty 62.5 microgram); fluticasone furoate, quantity: 200 microgram - inhalation, powder for - excipient ingredients: lactose monohydrate; magnesium stearate - asthma,trelegy ellipta is indicated for the maintenance treatment of asthma in adult patients who are not adequately controlled with a combination of inhaled corticosteroid and a long-acting beta2-agonist.,copd,trelegy ellipta is indicated for the maintenance treatment of adults with moderate to severe copd who require treatment with lama+laba+ics.,trelegy ellipta is not indicated for the initiation of therapy in copd.

Incruse Ellipta (previously Incruse) Evrópusambandið - enska - EMA (European Medicines Agency)

incruse ellipta (previously incruse)

glaxosmithkline (ireland) limited - umeclidinium bromide - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).,

ANORO ELLIPTA 62.5/25 umeclidinium (as bromide)/vilanterol (as trifenatate) 62.5 microgram/25 microgram powder for inhalation Ástralía - enska - Department of Health (Therapeutic Goods Administration)

anoro ellipta 62.5/25 umeclidinium (as bromide)/vilanterol (as trifenatate) 62.5 microgram/25 microgram powder for inhalation

glaxosmithkline australia pty ltd - umeclidinium bromide, quantity: 74.2 microgram (equivalent: umeclidinium, qty 62.5 microgram); vilanterol trifenatate, quantity: 40 microgram (equivalent: vilanterol, qty 25 microgram) - inhalation, powder for - excipient ingredients: magnesium stearate; lactose monohydrate - anoro ellipta is indicated as a long-term once daily maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).

Rolufta Ellipta (previously Rolufta) Evrópusambandið - enska - EMA (European Medicines Agency)

rolufta ellipta (previously rolufta)

glaxosmithkline trading services limited - umeclidinium bromide - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - rolufta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).,